Compare Huntington Bancshares Incorporated (HBAN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs State Street SPDR S&P Biotech ETF — how do they compare? Huntington Bancshares Incorporated trades at $15.31 (market cap $31.04B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Huntington Bancshares Incorporated is far larger — about 3.1× State Street SPDR S&P Biotech ETF's market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HBAN | XBI | |
|---|---|---|
Market Cap | $31.04B | $10.11B |
Volume | 23,864,172 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $19.27 | $169.55 |
52-Week Low | $15.02 | $104.99 |
Typical Hold Time | 52 Days | 38 Days |
Enterprise Value | $49.57B | — |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.28, up 0.73% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bearish technical signal with key support at $15 and resistance at $16, while fundamentals show a P/E of 11.82 and net income margin of 24.77%. Recent news highlights a cut in 2027 earnings outlook due to interest rate pressures, though the company maintains shareholder returns via dividends and buybacks.
The outlook for HBAN is cautious, with near-term headwinds from margin compression and loan growth challenges offset by a solid balance sheet and analyst consensus price target of $19.60. Risks include persistent interest rate pressures and competitive lending markets, but the stock offers value appeal with a dividend yield and institutional support.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
